Crescent Biopharma, Inc. (CBIO) Earnings History
Net Loss15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Crescent Biopharma, Inc. (CBIO) Earnings Overview
As of July 8, 2026, Crescent Biopharma, Inc. (CBIO) reported trailing twelve-month net income of -$162M, reflecting -815.0% year-over-year growth. The company earned $-5.33 per diluted share over the past four quarters, with a net profit margin of -1419.6%.
Looking at the long-term picture, CBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of $4M in fiscal 2012.
Crescent Biopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), IMVT (-$506M net income), KYMR (-$315M net income, -794.4% margin), CBIO has room to improve margins relative to the peer group. Compare CBIO vs RCUS →
CBIO Earnings vs Peers
Earnings metrics vs comparable public companies
CBIO Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$154M | -217.3% | -$153M | $-12.81 | -1419.6% | -1407.5% |
| 2024 | -$49M | -31.5% | -$50M | $-1.40 | - | - |
| 2023 | -$37M | +21.0% | -$39M | $-0.58 | -368994.2% | -392752.9% |
| 2022 | -$47M | +26.4% | -$47M | $-0.89 | -62251.7% | -63204.4% |
| 2021 | -$63M | -24.3% | -$63M | $-1.23 | -5469.0% | -5470.7% |
| 2020 | -$51M | +5.7% | -$52M | $-1.12 | -502.1% | -506.8% |
| 2019 | -$54M | -12.1% | -$61M | $-1.34 | - | - |
| 2018 | -$48M | -45.0% | -$52M | $-1.18 | - | - |
| 2017 | -$33M | -4.6% | -$34M | $-1.13 | - | - |
| 2016 | -$32M | -149.1% | -$32M | $-1.50 | -171945.1% | -172505.3% |
| 2015 | -$13M | -14.8% | -$13M | $-0.67 | -63.6% | -63.7% |
| 2014 | -$11M | -4.9% | -$11M | $-0.60 | -74.0% | -74.1% |
| 2013 | -$11M | -390.1% | -$11M | $-8.87 | -265.6% | -265.7% |
| 2012 | $4M | +159.8% | $4M | $3.06 | 24.0% | 23.8% |
| 2011 | -$6M | - | -$6M | $-5.11 | -160.3% | -159.5% |
Download Data
Export CBIO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CBIO — Frequently Asked Questions
Quick answers to the most common questions about buying CBIO stock.
What is CBIO earnings per share (EPS)?
CBIO trailing twelve-month (TTM) diluted EPS is $-5.33, reflecting -815.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Crescent Biopharma, Inc.'s net income?
Crescent Biopharma, Inc. (CBIO) trailing twelve-month net income is $-162M as of 2025. Earnings declined -815.0% year-over-year.
Is CBIO profitable?
CBIO is not currently profitable on a TTM basis, reporting a net loss of $-162M. Net margin is -1419.6%. Investors should monitor for a return to profitability.
What is CBIO's earnings growth rate?
CBIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are CBIO's profit margins?
Crescent Biopharma, Inc. net profit margin is -1419.6%, operating margin is -1407.5%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -164.2%.
Is CBIO growing earnings?
CBIO earnings are declining — EPS fell -815.0% year-over-year. TTM net income dropped to $-162M. This contrasts with the 5-year CAGR of N/A.
What was CBIO's best earnings year?
Crescent Biopharma, Inc.'s highest annual net income on record is $4M, achieved in fiscal year 2012. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were CBIO's earnings last quarter?
CBIO's most recent reported quarter was Q1 2026. Net income was $-23M with diluted EPS of $-0.70. For a full breakdown of all quarters, see the quarterly earnings table on this page.